Zai Lab and Novocure reported positive results from the PANOVA-3 trial, showing improved overall survival in pancreatic cancer patients using TTFields therapy with chemotherapy. Plans for regulatory approval are underway, with Zai Lab focusing on China and Novocure aiming for global approval.